机构投资者增加在AbbVie的股份,这比收入估计数低,增加了收入。 Institutional investors boost holdings in AbbVie, which beat earnings estimates and raised revenue.

Guerra顾问和CFM财富伙伴等机构投资者增加了在AbbVie Inc.的股份,AbbVie Inc.是一家制药公司,市场上限为3 212.9亿美元。 Institutional investors like Guerra Advisors and CFM Wealth Partners have increased their holdings in AbbVie Inc., a pharmaceutical company with a market cap of $321.29 billion. AbbVie的股票获得“机动购买”评级,价格目标为211.29美元。 AbbVie's stock received a "Moderate Buy" rating with a price target of $211.29. 该公司报告,每股收入为2.46美元,殴打估计数为0.06美元,其收入逐年增长8.4%。 The company reported earnings of $2.46 per share, beating estimates by $0.06, and its revenue increased by 8.4% year-over-year. AbbVie的产品系列包括Humira、Skyrizi和Rinvoq。 AbbVie's product line includes Humira, Skyrizi, and Rinvoq. 该公司还宣布季度股息为每股1.64美元,将于8月15日支付。 The company also declared a quarterly dividend of $1.64 per share, to be paid on August 15th.